Malin Corporation plc reported an intrinsic value of €9.36 per share as of June 30, 2026, according to a valuation update published on Tuesday. The company’s total intrinsic value increased to €40.7 million from €39.9 million at December 31, 2025, driven by foreign-exchange effects and the unwinding of discount rates over the period.
By August 24, 2026, Malin’s intrinsic value per share had declined 12% to €8.28. The reduction reflected a lower fair-value assessment for Kymab, a portfolio company, alongside a modest decrease in cash due to normal operating outflows. Malin’s cash position stood at €11.6 million on June 30, down from €12.9 million at year-end 2025, and was estimated at roughly €11.2 million by August 24.
Corporate operating cash expenses totaled €0.8 million in the first half of 2026. The company’s cash position also benefited from a January 2025 transaction tied to Poseida Therapeutics, in which Malin received an initial payment of approximately US$106.5 million for its roughly 12% stake. Malin remains eligible for up to an additional US$47.3 million through contingent value rights (CVRs) linked to future milestones, with the estimated fair value of these CVRs at €13.5 million as of August 24, 2026.
Malin’s valuation of Kymab will be reduced to zero in the second half of 2026 following Sanofi’s July 24 announcement that it would discontinue clinical development of Amlitelimab for moderate-to-severe atopic dermatitis. The decision removes a key milestone that had supported Kymab’s valuation.
The company is also engaged in discussions with other investors in Viamet Pharmaceuticals regarding a potential restructuring that could include a direct investment in Mycovia Pharmaceuticals, though no final terms have been disclosed.
